Siponimod hemifumarate

Cat. No.: HY-12355A

CAS No.: 1234627-85-0

Molecular Formula: $C_{29}H_{35}F_3N_2O_3 \cdot {}_1/_2C_4H_4O_4$

Molecular Weight: 574.63

Target: LPL Receptor

Pathway: GPCR/G Protein

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Siponimod (BAF-312) hemifumarate is a potent and selective sphingosine-1-phosphate (S1P) receptor modulator. Siponimod hemifumarate is selective for S1P1 and S1P5 receptors over S1P2, S1P3, and S1P4 (EC_{50}s of 0.39, 0.98, >10000, >1000, and 750 nM, respectively). Siponimod hemifumarate can be used for multiple sclerosis (MS) research[1][2].

IC_{50} & Target				
	S1PR1 0.39 nM (EC50)	S1PR5 0.98 nM (EC50)	S1PR4 750 nM (EC50)	S1PR3 >1000 nM (EC50)
	S1PR2 >10000 nM (EC50)			

CUSTOMER VALIDATION

- Proc Natl Acad Sci U S A. 2019 May 21;116(21):10557-10562.
- Vet Microbiol. 2021, 109177.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Pan S, et al. Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator. ACS Med Chem Lett. 2013 Jan 4;4(3):333-7.

[2]. McGinley M, et al. Prospects of siponimod in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2018 Jul 17;11:1756286418788013.

[3]. Behrangi N, et al. Mechanism of Siponimod: Anti-Inflammatory and Neuroprotective Mode of Action. Cells. 2019 Jan 7;8(1):24.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA